NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP ebevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery-MedSci.cn

NIRVANA-1: A multicentre randomized study comparing carboplatin-paclitaxel (CP) followed by niraparib (nira) to CP ebevacizumab (bev) followed by nira-bev in patients with FIGO stage III ovarian high-grade epithelial cancer and no residual disease after upfront surgery

Freyer, G; Martin, AJG; Raspagliesi, F; Peron, J; Van Nieuwenhuysen, E; Hasegawa, K; Lim, MC; Ray-Coquard, IL

ANNALS OF ONCOLOGY, 2022; 33 (7): S826

科室
- - 订阅+
  - 更多科室
工具
服务